Dr. Shanu Modi, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 174
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 234469
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 174
- Services billed
- 384
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 290 | 141 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in New York, NY | 100 |
| Letrozole Other prescribers in New York, NY | 55 |
| Tamoxifen Citrate Other prescribers in New York, NY | 51 |
| Ibrance (palbociclib) | 25 |
| Verzenio (abemaciclib) | 21 |
| Exemestane | 21 |
| Kisqali (ribociclib succinate) | 17 |
| Orserdu (elacestrant hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 31 payments worth $60,377 in total to this clinician.
| Whitehall International Inc | $14,459 |
|---|---|
| AstraZeneca UK Limited | $9,160 |
| Daiichi Sankyo Company LTD | $8,170 |
| AstraZeneca Pharmaceuticals LP | $5,463 |
| Boehringer Ingelheim International GmbH | $4,440 |
| Gilead Sciences, Inc. | $4,366 |
| Jazz Pharmaceuticals Inc. | $4,120 |
| Genentech USA, Inc. | $3,062 |
| Consulting Fee | $41,208 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $14,419 |
| Travel and Lodging | $4,365 |
| Food and Beverage | $385 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Whitehall International Inc Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) TUKYSA · ONCOLOGY | $14,419 |
| Boehringer Ingelheim International GmbH Jun 25, 2025 | Consulting Fee | $4,440 |
| Jazz Pharmaceuticals Inc. Dec 22, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $4,120 |
| AstraZeneca UK Limited Apr 17, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,100 |
| Daiichi Sankyo Company LTD Mar 6, 2025 | Travel and Lodging Enhertu · ONCOLOGY · travel to KOBE-SHI, Japan · in-kind | $3,946 |
| Daiichi Sankyo Company LTD Mar 14, 2025 | Consulting Fee Enhertu · ONCOLOGY | $3,880 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting Fee ENHERTU · Oncology | $3,690 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Herceptin; Perjeta; Phesgo · BioOncology | $2,936 |
| Gilead Sciences, Inc. Jun 12, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4146659;VEM US;10671455 | $2,880 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee | $2,055 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Dec 22, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $4,120 |
| E.r. Squibb & Sons, L.l.c. Dec 12, 2025 | Consulting Fee | $1,710 |
| Gilead Sciences, Inc. Dec 12, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289892;GTF;10671455 | $360 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting Fee ENHERTU · Oncology | $3,690 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee Enhertu · ONCOLOGY | $1,713 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Consulting Fee ENHERTU · Oncology | $1,640 |
| AstraZeneca UK Limited Nov 5, 2025 | Consulting Fee | $685 |
| F. Hoffmann-la Roche AG Oct 20, 2025 | Consulting Fee Perjeta · BioOncology | $1,230 |
| AstraZeneca Pharmaceuticals LP Jul 24, 2025 | Consulting Fee | $1,640 |
| Daiichi Sankyo Inc. Jul 23, 2025 | Consulting Fee Enhertu · ONCOLOGY | $685 |
| Gilead Sciences, Inc. Jul 17, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253420;VEM US;10671455 | $960 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Herceptin; Perjeta; Phesgo · BioOncology | $2,936 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Herceptin; Perjeta; Phesgo · BioOncology · travel to New York City, NY | $55.80 |
| Boehringer Ingelheim International GmbH Jun 25, 2025 | Consulting Fee | $4,440 |
| Gilead Sciences, Inc. Jun 12, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4146659;VEM US;10671455 | $2,880 |
| AstraZeneca UK Limited May 14, 2025 | Consulting Fee ENHERTU · Oncology Company’s descriptionResearch Related Service | $685 |
| AstraZeneca UK Limited Apr 17, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,100 |
| Daiichi Sankyo Company LTD Mar 14, 2025 | Consulting Fee Enhertu · ONCOLOGY | $3,880 |
| Whitehall International Inc Mar 14, 2025 | Travel and Lodging TUKYSA · ONCOLOGY · travel to MONTREAL, Canada | $39.08 |
| Whitehall International Inc Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) TUKYSA · ONCOLOGY | $14,419 |
| Daiichi Sankyo Company LTD Mar 6, 2025 | Travel and Lodging Enhertu · ONCOLOGY · travel to KOBE-SHI, Japan · in-kind | $3,946 |
| Daiichi Sankyo Company LTD Mar 6, 2025 | Travel and Lodging Enhertu · ONCOLOGY · travel to KOBE-SHI, Japan · in-kind | $324 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee | $2,055 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $1,740,809 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
Pfizer Inc. - A single arm open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locallyadvanced or metastatic HER2 breast cancer
Pfizer Inc. - A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
AstraZeneca Pharmaceuticals LP - First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT03401385 - Ph 1 Dose Escalation of RUNIMOTAMAB HER2 expressing cancers
Genentech, Inc. - BNT323-03
BioNTech SE - Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo Inc. · Completed · NCT03734029
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.